Amminger GP, et al. - In NEURAPRO, a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders, no benefits of n-3 PUFAs over placebo could be demonstrated. Researchers here examined biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) collected as part of NEURAPRO on 218 participants with longitudinal biomarker data in order to determine if clinical outcomes could be predicted using the n-3 PUFAs measures in erythrocytes at baseline and month 6. At both follow-up time points, increases of the n-3 index, EPA, and DHA were predictive of less severe psychopathology and better functioning. Findings suggest the possible therapeutic effects of n-3 PUFAs in ultra-high-risk individuals. They suggest considering this finding in early intervention and treatment guidelines, as n-3 PUFA supplementation can easily and safely be practiced in a wide variety of settings, from primary care to specialist services.